MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/j.1540-8183.2011.00632.x

Медицинская библиотека · Journal of interventional cardiology · 2011

Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Mahmoudi Michael, Delhaye Cedric, Wakabayashi Kohei, Torguson Rebecca, Xue Zhenyi, Suddath William O, Satler Lowell F, Kent Kenneth M, Pichard Augusto D, Waksman Ron

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The adjunctive use of eptifibatide in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains controversial. We therefore set out to determine the safety and efficacy of eptifibatide in this population.

METHODS

The study comprised 857 consecutive patients who underwent primary PCI for STEMI at the Washington Hospital Center. Three hundred eighteen patients also received adjunctive therapy with eptifibatide. Patients who had received thrombolysis prior to undergoing cardiac catheterization were excluded. The primary end-point was all-cause mortality and the composite of all-cause mortality or Q-wave MI. The primary safety end-point was the rate of thrombolysis in myocardial infarction (TIMI) major bleeding.

RESULTS

The eptifibatide group was younger, had a higher body mass index, and a lower proportion of patients with systemic hypertension, diabetes mellitus, previous history of ischemic heart disease, coronary revascularization, and congestive heart failure. This cohort also used bivalirudin less often (23.3% vs. 72%; P < 0.001). Following multivariable analysis, the eptifibatide group had a significantly lower rate of all-cause mortality (hazard ratio 0.55; 95% confidence interval 0.34-0.89; P = 0.01) and the composite of all-cause mortality or Q-wave MI (hazard ratio 0.59; 95% confidence interval 0.37-0.95; P = 0.03) at 6 months. The rate of TIMI major bleeding was similar in both groups (hazard ratio 0.54; 95% confidence interval 0.25-1.17; P = 0.12).

CONCLUSION

The adjunctive use of eptifibatide in patients presenting with STEMI may be associated with improved clinical outcomes. (J Interven Cardiol 2011;24:351-356).

Для цитирования: Mahmoudi Michael, Delhaye Cedric, Wakabayashi Kohei, Torguson Rebecca, Xue Zhenyi, Suddath William O, Satler Lowell F, Kent Kenneth M, Pichard Augusto D, Waksman Ron. Integrilin in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.. Journal of interventional cardiology. 2011. DOI: 10.1111/j.1540-8183.2011.00632.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.